Gland Pharma appoints Yao Fang as Additional Director to the board

  • India Infoline News Service |
  • 11 Mar, 2022 |
  • 10:14 AM
Gland Pharma Ltd has announced to the exchanges regarding appointment of Yao Fang as an Additional Director, categorized as Non-Independent and Non-Executive Director, with effect from March 10, 2022 as a Director liable to retire by rotation.

Yao Fang is the Executive President of Fosun International Limited (listed on the Hong Kong Stock Exchange). Yao Fang joined the Fosun Group in April 2010 and he is also a Non-Executive Director of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange).

Prior to joining the Fosun Group, from 1993 to 2009, Yao Fang was successively the Assistant General Manager of the International Business Department of Shanghai Wanguo Securities Company Limited (now known as Shenyin & Wanguo Securities Company Limited), General Manager of Shanghai Industrial Assets Management Company Limited, General Manager of Shanghai Industrial Management (Shanghai) Company Limited, Managing Director of Shanghai Industrial Pharmaceutical Investment Company Limited (a company delisted from the Shanghai Stock Exchange), Chairman of Shanghai Overseas Company, Non-Executive Director of Lianhua Supermarket Holdings Company Limited (a company listed on the Hong Kong Stock Exchange), Executive Director of Shanghai Industrial Holdings Limited (a company listed on the Hong Kong Stock Exchange). Yao Fang was a Non-Executive Director of BioSino Bio-Technology and Science Incorporation (a company listed on the Hong Kong Stock Exchange) during 2011 to 2014.

Yao Fang obtained a bachelor’s degree in Economics from Fudan University in July, 1989 and a Master’s degree in Business Administration from The Chinese University of Hong Kong in December, 1993.

Also, the board has informed the re-appointment of Srinivas Sadu as Managing Director and CEO of the Company for a period of 5 years, with effect from April 25, 2022; subject to the approval of Members of the Company.

At around 10:18 AM, Gland Pharma was trading at Rs3340.80 per share lower by 0.57% on the BSE.

Invest wise with Expert advice

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
ad IconAd Image

Most Read News

Article Image
  • 14 March, 2022 |
  • 7:03 AM

The US Federal committee's meeting will conclude on March 16, 2022.

Most Shared News

No Record Found